Asset Details
Do you wish to reserve the book?
Evolution of platinum resistance in high-grade serous ovarian cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Evolution of platinum resistance in high-grade serous ovarian cancer
Do you wish to request the book?
Evolution of platinum resistance in high-grade serous ovarian cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Evolution of platinum resistance in high-grade serous ovarian cancer
2011
Overview
High-grade serous ovarian cancers account for most ovarian-cancer mortality. Although this disease initially responds well to platinum-based chemotherapy, relapse and progression to chemotherapy resistance are frequently seen. Time to relapse after first-line therapy is a predictor of response to secondary platinum treatment: more than 12 months is associated with high chance of a secondary response, whereas relapses within 6 months generally indicate platinum resistance. In this Personal View we discuss whether patterns of response, relapse, and the development of drug resistance in high-grade serous ovarian cancers are related to distinct underlying molecular and cellular biological characteristics. In particular, we propose that rapid relapse with platinum-resistant disease is due to minor subpopulations of intrinsically resistant cancer cells at presentation.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Female
/ Hematology, Oncology and Palliative Medicine
/ Humans
/ Neoplasms, Cystic, Mucinous, and Serous - drug therapy
/ Neoplasms, Cystic, Mucinous, and Serous - mortality
/ Neoplasms, Cystic, Mucinous, and Serous - pathology
/ Organoplatinum Compounds - adverse effects
/ Organoplatinum Compounds - therapeutic use
/ Ovarian Neoplasms - drug therapy
/ Ovarian Neoplasms - mortality
/ Ovarian Neoplasms - pathology
/ Platinum Compounds - adverse effects
